Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

IXICO Signs New Contract for Specialist Imaging Clinical Trial Services

By IXICO | July 6, 2017

IXICO, the digital technologies company serving neuroscience, announces that it has signed a new contract for specialist imaging clinical trial services. The contract is for a Phase II clinical trial of patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease (AD). Sponsored by specialist Spanish biotech company Araclon Biotech, a Grifols company, this phase II of the study is designed to establish the dosage regimen for the therapy, as well as confirm the treatment safety and tolerability data obtained in phase I.

Using our TrialTracker digital platform, IXICO will collate both PET and MRI scans acquired at specialist imaging centres across Europe. This data will be then analysed using IXICO’s patent protected image analysis technology, which has been customised to evaluate patient eligibility, assess target engagement and quantify drug effects in AD patients.

Giulio Cerroni, Chief Executive of IXICO, commented: “We are delighted to be working with Araclon Biotech which continues our success in providing our customers with a solution that spans both PET and MR imaging services. It is a great example of IXICO’s growing value to the biopharmaceutical industry and reinforces our confidence in revenue growth this financial year.”

Manuel Sarasa, Chief Scientific Officer of Araclon, commented: “It is an important milestone for us to initiate phase II of clinical trials for our Azheimer´s vaccine -ABvac40- after receiving approval from the Spanish Agency of Medicinal Products and Medical Service. We are a little closer to achieving our goal, so it is fundamental for us to incorporate the best-in-class suppliers, such as IXICO, to work togethe


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50